Relmada Therapeutics, Inc. RLMD Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$58.88M-2.6% | -$57.39M-2.2% | -$56.17M+17.2% | -$67.81M+10.4% | -$75.71M+5.3% | ||
| $11.29M-18.8% | $13.91M-23.9% | $18.26M-19.2% | $22.6M-11.2% | $25.46M-15.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$297.57K-175% | $398.25K— | —— | —— | —— | ||
| -$42.79M+6.6% | -$45.79M-14.5% | -$39.99M+19.9% | -$49.92M+12.1% | -$56.79M-9.7% | ||
| $232.86M+178% | $83.83M+4,837% | $1.7M-62.9% | $4.58M-17.6% | $5.55M-54.0% | ||
| $34.13M-4.4% | $35.69M-14.7% | $41.83M-22.7% | $54.1M-13.3% | $62.42M-1.9% | ||
| $23.02M-14.4% | $26.88M-9.8% | $29.81M-19.3% | $36.92M-17.6% | $44.82M-2.9% | ||
| -$198.73M-313% | -$48.14M-220% | $40.14M-19.0% | $49.53M-12.9% | $56.86M+10.3% | ||
| —— | —— | —— | —— | —— | ||
| $230.23M+146% | $93.64M+32.7% | $70.59M+50.8% | $46.82M+100% | $23.41M+9,387% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $12.19M-17.7% | $14.81M-18.9% | $18.26M-19.2% | $22.6M-11.2% | $25.46M-15.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$152.03K-91.9% | -$79.21K-214% | $69.56K-76.7% | $298.83K-22.3% | $384.75K+2.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $29.88K+368% | $6.39K+43.0% | ||
| —— | —— | —— | —— | —— | ||
| $232.86M+178% | $83.83M+4,837% | $1.7M-62.9% | $4.58M-17.6% | $5.55M-54.0% | ||
| $34.13M-4.4% | $35.69M-14.7% | $41.83M-22.7% | $54.1M-13.3% | $62.42M-1.9% | ||
| $120.42K+64.9% | $73.02K-67.9% | $227.25K-23.9% | $298.6K+6.5% | $280.34K-2.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $37.33M+15.8% | $32.22M+14.9% | $28.04M-16.6% | $33.6M-2.0% | $34.3M-9.1% | ||
| $1.92M+37.2% | $1.4M-16.1% | $1.66M-26.8% | $2.27M-22.0% | $2.91M-17.4% | ||
| $1.47M-14.5% | $1.72M+2.8% | $1.67M-38.6% | $2.72M-20.4% | $3.41M-12.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$297.57K-175% | $398.25K— | —— | —— | —— | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Relmada Therapeutics, Inc. generate?
- Relmada Therapeutics, Inc. (RLMD) generated -$42.8M in operating cash flow over the trailing twelve months.
- What is Relmada Therapeutics, Inc.'s free cash flow?
- After $182.1M of capital expenditures, Relmada Therapeutics, Inc.'s free cash flow was -$209.9M over the trailing twelve months, down 116.5% year over year.
- Where does Relmada Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Relmada Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.